Full Text Journal Articles by
Author Amadeo Parissenti

Advertisement

Find full text journal articles






Cystathionine gamma-lyase/H2 S signaling facilitates myogenesis under aging and injury condition.

Yanjie Zhang, Laura Masters, Yuehong Wang, Lingyun Wu, Yanxi Pei, Baoqing Guo, Amadeo Parissenti, Simon J Lees, Rui Wang, Guangdong Yang,

Hydrogen sulfide (H<sub>2</sub> S) can be endogenously produced and belongs to the class of signaling molecules known as gasotransmitters. Cystathionine gamma-lyase (CSE)-derived H<sub>2</sub> S is implicated in the regulation of cell differentiation and the aging process, but the involvements of the CSE/H<sub>2</sub> S system in myogenesis upon aging and injury ... Read more >>

FASEB J (FASEB journal : official publication of the Federation of American Societies for Experimental Biology)
[2021, 35(5):e21511]

Cited: 0 times

View full text PDF listing >>



The RNA disruption assay is superior to conventional drug sensitivity assays in detecting cytotoxic drugs.

Jonathan P J Mapletoft, Renée J St-Onge, Baoqing Guo, Phillipe Butler, Twinkle J Masilamani, Lavina D'costa, Laura B Pritzker, Amadeo M Parissenti,

Conventional drug sensitivity assays used to screen prospective anti-cancer agents for cytotoxicity monitor biological processes associated with active growth and proliferation, used as proxies of cell viability. However, these assays are unable to distinguish between growth-arrested (but otherwise viable) cells and non-viable/dead cells. As a result, compounds selected based on ... Read more >>

Sci Rep (Scientific reports)
[2020, 10(1):8671]

Cited: 0 times

View full text PDF listing >>



Advertisement

Chemotherapy and Inflammatory Cytokine Signalling in Cancer Cells and the Tumour Microenvironment.

Derek W Edwardson, Amadeo M Parissenti, A Thomas Kovala,

Cancer is the result of a cell's acquisition of a variety of biological capabilities or 'hallmarks' as outlined by Hanahan and Weinberg. These include sustained proliferative signalling, the ability to evade growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and the ability to invade other tissue and metastasize. ... Read more >>

Adv Exp Med Biol (Advances in experimental medicine and biology)
[2019, 1152:173-215]

Cited: 0 times

View full text PDF listing >>



Efflux inhibition by H2S confers sensitivity to doxorubicin-induced cell death in liver cancer cells.

Eric Stokes, Tian Shuang, Yanjie Zhang, Yanxi Pei, Ming Fu, Baoqing Guo, Amadeo Parissenti, Lingyun Wu, Rui Wang, Guangdong Yang,

<h4>Aims</h4>Hydrogen sulfide (H<sub>2</sub>S), an important gasotransmitter, is involved in a variety of cellular functions and pathophysiologic processes. Drug resistance due to alterations in drug trafficking and metabolism severely limits the effectiveness of cancer therapy. This study examined the role of H<sub>2</sub>S in drug resistance in liver cancer cells.<h4>Materials and methods</h4>Human ... Read more >>

Life Sci (Life sciences)
[2018, 213:116-125]

Cited: 2 times

View full text PDF listing >>



Bile Acids Increase Doxorubicin Sensitivity in ABCC1-expressing Tumour Cells.

Simon Chewchuk, Tyler Boorman, Derek Edwardson, Amadeo M Parissenti,

Tumour cells possess or acquire various mechanisms to circumvent the cytotoxic effects of chemotherapy drugs. One such mechanism involves the overexpression of ABC transporters that facilitate the extrusion of a variety of structurally distinct chemotherapy drugs from the cytoplasm into the extracellular space. While specific ABC transporter inhibitors have been ... Read more >>

Sci Rep (Scientific reports)
[2018, 8(1):5413]

Cited: 2 times

View full text PDF listing >>



Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance.

Derek W Edwardson, Justin Boudreau, Jonathan Mapletoft, Carita Lanner, A Thomas Kovala, Amadeo M Parissenti,

Tumor Necrosis Factor alpha (TNF-α) has been shown to be released by tumor cells in response to docetaxel, and lipopolysaccharides (LPS), the latter through activation of toll-like receptor 4 (TLR4). However, it is unclear whether the former involves TLR4 receptor activation through direct binding of the drug to TLR4 at ... Read more >>

PLoS One (PloS one)
[2017, 12(9):e0183662]

Cited: 9 times

View full text PDF listing >>



Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.

Richard C Wang, Xinmei Chen, Amadeo M Parissenti, Anil A Joy, Jack Tuszynski, David N Brindley, Zhixiang Wang,

<h4>Introduction</h4>One of the main reasons for disease recurrence in the curative breast cancer treatment setting is the development of drug resistance. Microtubule targeted agents (MTAs) are among the most commonly used drugs for the treatment of breaset cancer and therefore overcoming taxane resistance is of primary clinical importance. Our group ... Read more >>

PLoS One (PloS one)
[2017, 12(8):e0182400]

Cited: 6 times

View full text PDF listing >>



Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.

Simon Chewchuk, Baoqing Guo, Amadeo Mark Parissenti,

Intrinsic or acquired drug resistance is a major impediment to the successful treatment of women with breast cancer using chemotherapy. We have observed that MCF-7 breast tumor cells selected for resistance to doxorubicin or epirubicin (MCF-7DOX2 and MCF-7EPI cells, respectively) exhibited increased expression of several members of the aldo-keto reductase ... Read more >>

PLoS One (PloS one)
[2017, 12(2):e0172244]

Cited: 3 times

View full text PDF listing >>



Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells.

Baoqing Guo, Adam Tam, Stacey A Santi, Amadeo M Parissenti,

<h4>Background</h4>The roles and mechanisms involved in starvation-induced autophagy in mammalian cells have been extensively studied. However, less is known about the potential role for autophagy as a survival pathway in acquired drug resistance in cancer cells under nutrient-rich conditions.<h4>Methods</h4>We selected MCF-7 breast tumor cells for survival in increasing concentrations of ... Read more >>

BMC Cancer (BMC cancer)
[2016, 16(1):762]

Cited: 19 times

View full text PDF listing >>



Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response.

Xiaobin Zheng, Neal Andruska, Michael J Lambrecht, Sisi He, Amadeo Parissenti, Paul J Hergenrother, Erik R Nelson, David J Shapiro,

Ovarian cancers often recur and tumors acquire resistance to chemotherapy due to overexpression of the ATP-dependent efflux pump, multidrug resistance protein 1 (MDR1/P-glycoprotein/ABCB1). Nontoxic small molecule inhibitors targeting MDR1 have remained largely elusive. Instead, in a novel application of our recently described estrogen receptor α (ERα) biomodulator, BHPI, we targeted ... Read more >>

Oncotarget (Oncotarget)
[2018, 9(19):14741-14753]

Cited: 8 times

View full text PDF listing >>



RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.

Rashmi Narendrula, Kyle Mispel-Beyer, Baoqing Guo, Amadeo M Parissenti, Laura B Pritzker, Ken Pritzker, Twinkle Masilamani, Xiaohui Wang, Carita Lannér,

<h4>Background</h4>Cellular stressors and apoptosis-inducing agents have been shown to induce ribosomal RNA (rRNA) degradation in eukaryotic cells. Recently, RNA degradation in vivo was observed in patients with locally advanced breast cancer, where mid-treatment tumor RNA degradation was associated with complete tumor destruction and enhanced patient survival. However, it is not ... Read more >>

BMC Cancer (BMC cancer)
[2016, 16:146]

Cited: 4 times

View full text PDF listing >>



A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.

Maureen Elizabeth Trudeau, Judith-Anne W Chapman, Baoqing Guo, Mark J Clemons, Rebecca A Dent, Roberta A Jong, Harriette J Kahn, Kathleen I Pritchard, Lei Han, Patti O'Brien, Lois E Shepherd, Amadeo M Parissenti,

This phase I/II neoadjuvant trial (ClinicalTrials.gov identifier NCT00066443) determined maximally-tolerated doses (MTD), dose-limiting toxicities, response-to-therapy, and explored the role of novel response biomarkers. MA.22 accrued T3N0, any N2 or N3, and T4 breast cancer patients. Treatment was 6 cycles of 3-weekly (Schedule A; N = 47) or 8 cycles of 2-weekly (Schedule ... Read more >>

Springerplus (SpringerPlus)
[2015, 4:631]

Cited: 4 times

View full text PDF listing >>



Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

Amadeo M Parissenti, Baoqing Guo, Laura B Pritzker, Kenneth P H Pritzker, Xiaohui Wang, Mu Zhu, Lois E Shepherd, Maureen E Trudeau,

In a prior substudy of the CAN-NCIC-MA.22 clinical trial (ClinicalTrials.gov identifier NCT00066443), we observed that neoadjuvant chemotherapy reduced tumor RNA integrity in breast cancer patients, a phenomenon we term "RNA disruption." The purpose of the current study was to assess in the full patient cohort the relationship between mid-treatment tumor ... Read more >>

Breast Cancer Res Treat (Breast cancer research and treatment)
[2015, 153(1):135-144]

Cited: 5 times

View full text PDF listing >>



RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.

Kenneth Pritzker, Laura Pritzker, Daniele Generali, Alberto Bottini, Maria Rosa Cappelletti, Baoqing Guo, Amadeo Parissenti, Maureen Trudeau,

<h4>Background</h4>As there is now evidence that switching clinical nonresponders early in primary systemic therapy to alternate treatment regimens can enhance survival in some breast cancer patients, the need for a robust intermediate endpoint that can guide treatment response across all tumor subtypes is urgent. Recently, chemotherapy drugs have been shown ... Read more >>

J Natl Cancer Inst Monogr (Journal of the National Cancer Institute. Monographs)
[2015, 2015(51):76-80]

Cited: 2 times

View full text PDF listing >>



Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.

Derek W Edwardson, Rashmi Narendrula, Simon Chewchuk, Kyle Mispel-Beyer, Jonathan P J Mapletoft, Amadeo M Parissenti,

Many clinical studies involving anti-tumor agents neglect to consider how these agents are metabolized within the host and whether the creation of specific metabolites alters drug therapeutic properties or toxic side effects. However, this is not the case for the anthracycline class of chemotherapy drugs. This review describes the various ... Read more >>

Curr Drug Metab (Current drug metabolism)
[2015, 16(6):412-426]

Cited: 17 times

View full text PDF listing >>



Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".

Chiara Foroni, Manuela Milan, Carla Strina, Mariarosa Cappelletti, Claudia Fumarola, Mara Bonelli, Ramona Bertoni, Giuseppina Ferrero, Mara Maldotti, Elena Takano, Daniele Andreis, Sergio Venturini, Giulia Brugnoli, Pier Giorgio Petronini, Vanessa Zanoni, Laura Pritzker, Kenneth Pritzker, Amadeo Parissenti, Daniele Santini, Stephen B Fox, Alberto Bottini, Daniele Generali,

The study investigated the anti-tumour effect of zoledronic acid (ZA) administered alone in a biological window therapy in naïve bone-only metastatic and locally advanced breast cancer (LABC) patients. 33 patients with LABC (Group 1) and 20 patients with a first diagnosis of bone metastasis only (Group 2) received 4 mg ... Read more >>

Breast Cancer Res Treat (Breast cancer research and treatment)
[2014, 144(1):113-121]

Cited: 8 times

View full text PDF listing >>



Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.

Harris Wang, The Vo, Ali Hajar, Sarah Li, Xinmei Chen, Amadeo M Parissenti, David N Brindley, Zhixiang Wang,

<h4>Background</h4>Chemoresistance is a major factor involved in a poor response and reduced overall survival in patients with advanced breast cancer. Although extensive studies have been carried out to understand the mechanisms of chemoresistance, many questions remain unanswered.<h4>Methods</h4>In this research, we used two isogenic MCF-7 breast cancer cell lines selected for ... Read more >>

BMC Cancer (BMC cancer)
[2014, 14:37]

Cited: 24 times

View full text PDF listing >>



Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel.

Stephen R Armstrong, Rashmi Narendrula, Baoqing Guo, Amadeo M Parissenti, Katherine L McCallum, Stephanie Cull, Carita Lannér,

<h4>Unlabelled</h4><h4>Background</h4>Current protocols for the treatment of ovarian cancer include combination chemotherapy with a platinating agent and a taxane. However, many patients experience relapse of their cancer and the development of drug resistance is not uncommon, making successful second line therapy difficult to achieve. The objective of this study was to ... Read more >>

J Ovarian Res (Journal of ovarian research)
[2012, 5(1):40]

Cited: 10 times

View full text PDF listing >>



Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.

Allan D Heibein, Baoqing Guo, Jason A Sprowl, David A Maclean, Amadeo M Parissenti,

<h4>Background</h4>Since proteins involved in chemotherapy drug pharmacokinetics and pharmacodynamics have a strong impact on the uptake, metabolism, and efflux of such drugs, they likely play critical roles in resistance to chemotherapy drugs in cancer patients.<h4>Methods</h4>To investigate this hypothesis, we conducted a whole genome microarray study to identify difference in the ... Read more >>

BMC Cancer (BMC cancer)
[2012, 12:381]

Cited: 29 times

View full text PDF listing >>



Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.

Jason A Sprowl, Kerry Reed, Stephen R Armstrong, Carita Lanner, Baoqing Guo, Irina Kalatskaya, Lincoln Stein, Stacey L Hembruff, Adam Tam, Amadeo M Parissenti,

INTRODUCTION: The taxanes paclitaxel and docetaxel are widely used in the treatment of breast, ovarian, and other cancers. Although their cytotoxicity has been attributed to cell-cycle arrest through stabilization of microtubules, the mechanisms by which tumor cells die remains unclear. Paclitaxel has been shown to induce soluble tumor necrosis factor ... Read more >>

Breast Cancer Res (Breast cancer research : BCR)
[2012, 14(1):R2]

Cited: 22 times

View full text PDF listing >>



The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.

Kerry Reed, Amadeo M Parissenti,

Despite their clearly distinct pathophysiologies, HIV and cancer are diseases whose response to chemotherapy treatment varies substantially amongst patients, in particular for those with prior drug exposure. This has been attributed, in part, to elevated expression of the ABCB1 drug transporter in some patients, which results in reduced drug accumulation ... Read more >>

Pharmacogenomics (Pharmacogenomics)
[2011, 12(10):1465-1483]

Cited: 7 times

View full text PDF listing >>



miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.

A Holleman, I Chung, R R Olsen, B Kwak, A Mizokami, N Saijo, A Parissenti, Z Duan, E E Voest, B R Zetter,

Cancer cell resistance to paclitaxel continues to be a major clinical problem. In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role ... Read more >>

Oncogene (Oncogene)
[2011, 30(43):4386-4398]

Cited: 63 times

View full text PDF listing >>



Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.

Amadeo M Parissenti, Judy-Anne W Chapman, Harriette J Kahn, Baoqing Guo, Lei Han, Patti O'Brien, Mark P Clemons, Roberta Jong, Rebecca Dent, Barbara Fitzgerald, Kathleen I Pritchard, Lois E Shepherd, Maureen E Trudeau,

The CAN-NCIC-MA22 phase I/II clinical trial evaluated women with locally advanced or inflammatory breast cancer treated with epirubicin and docetaxel at 2 or 3 weekly intervals in sequential cohorts. The relationship between various biomarkers and treatment response was assessed. Breast biopsy cores were obtained from 50 patients pre-, mid-, and ... Read more >>

Breast Cancer Res Treat (Breast cancer research and treatment)
[2010, 119(2):347-356]

Cited: 12 times

View full text PDF listing >>



Comparison of bisulfite sequencing PCR with pyrosequencing for measuring differences in DNA methylation.

Kerry Reed, Matthew L Poulin, Liying Yan, Amadeo M Parissenti,

DNA methylation strongly affects chromatin structure and the regulation of gene expression. For many years, bisulfite sequencing PCR (BSP) has served as the "gold standard" for measuring DNA methylation. However, with the evolution of pyrosequencing as a tool to evaluate DNA methylation, the need arises to compare the relative efficiencies ... Read more >>

Anal Biochem (Analytical biochemistry)
[2010, 397(1):96-106]

Cited: 46 times

View full text PDF listing >>



Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.

Zachary W Veitch, Baoqing Guo, Stacey L Hembruff, Adam J Bewick, Allan D Heibein, Jamei Eng, Stephanie Cull, David A Maclean, Amadeo M Parissenti,

<h4>Objectives</h4>Recent studies suggest that tumor cells overexpressing aldoketoreductases (AKRs) exhibit increased resistance to DNA damaging agents such as anthracyclines. AKRs may induce resistance to the anthracycline doxorubicin by catalyzing its conversion to the less toxic 13-hydroxy metabolite doxorubicinol. However, it has not been established whether during selection for anthracycline resistance, ... Read more >>

Pharmacogenet Genomics (Pharmacogenetics and genomics)
[2009, 19(6):477-488]

Cited: 25 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0754 s